oncology
CHICAGO—A 25 per cent risk reduction for esophageal cancer was found to be associated with prophylactic therapy consisting of a proton pump inhibitor (PPI) and aspirin in the phase three randomized ASPECT multicenter study from the United Kingdom reported at …
CHICAGO—Patients with resectable and “borderline resectable” pancreatic cancers treated with chemoradiation before surgery (followed by adjuvant chemotherapy) had significantly improved outcomes compared to those randomized to have surgery first and adjuvant chemotherapy in the Dutch Pancreatic Cancer Group’sPREOPANC-1 randomized, controlled, …
CHICAGO—Patients with newly-diagnosed hormone-sensitive metastatic prostate cancer (mPC) who had prostate radiotherapy (RT) before their androgen deprivation therapy (ADT) lived longer than those treated with standard ADT alone in a retrospective analysis—the largest single-center experience to date of primary tumor-directed …
CHICAGO—A gene test that predicts for relapse in women with estrogen receptor positive early breast cancer can identify patients with low-risk disease who could safely avoid extending their endocrine therapy beyond the standard five years, according to study findings reported …
CHICAGO—Men who had breast-conserving therapy (BCT) including radiation for their early breast cancer lived longer than those who had total or partial mastectomy—with or without radiation—in findings from a large retrospective survey of male breast cancer reported at the 2018 …
CHICAGO—A “cluster randomized controlled trial” of treatment for patients with advanced cancers found that the use of standardized geriatric assessments significantly increased the number and quality of discussions about age-related concerns in comparison with usual care and also resulted in …
CHICAGO—Women and men were treated differently for the same tumor stages of head and neck cancer (HNC) and had different outcomes in a study with patients surveyed over a fifteen-year period in Santa Clara, California. The findings—using the generalized competing …
CHICAGO, IL—Patients whose non-small cell lung cancers (NSCLC) expressed more than one per cent of the programmed death ligand-1 (PD-L1) tumor proportion score (TPS) lived longer when treated with the anti programmed death 1 (PD-1) antibody pembrolizumab than a control …
BARCELONA—Ultrahypofractionated radiation (U-HF) delivered in only seven fractions (each triple the usual dose) in two and a half weeks was just as effective for treating intermediate-risk prostate cancer—with no greater toxicity—as a standard protocol with 39 fractions over eight-weeks in …
BARCELONA—Women who develop breast symptoms—especially lumps—between regular mammography screening examinations are up to four times more likely to have a diagnosis of breast cancer soon after than women who do not have symptoms according to findings of a massive study …
BARCELONA—More pre-menopausal women who have estrogen receptor (ER) positive advanced breast cancer could be spared chemotherapy—according to latest findings from the MONALEESA-7 double-blind randomized phase 3 trial in which either placebo (PBO) or the cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib …
BARCELONA—A multicenter nationwide Italian study of patients with ductal carcinoma in situ (DCIS) treated with breast conservative surgery (BCS) and whole breast radiotherapy (RT) has updated risk criteria to help women opt for gentler treatments and avoid toxicities from overtreatment.…